Addex Pharmaceuticals / Addex to Host FY2009 Financial Results Conference Call on Feb. 23 verarbeitet und übermittelt durch Hugin. Für den Inhalt der Mitteilung ist der Emittent verantwortlich. 

Geneva,  Switzerland, 16 February  2010 - Addex  Pharmaceuticals (SWX:ADXN), the
allosteric modulation company, will discuss its 2009 full year financial results
during  a conference call and  webcast for investors, analysts  and the media on
Tuesday, 23 February 2010 at 16:00 CET. The financial results press release will
be  issued prior to the start of trading  on the SIX Swiss Exchange stock market
earlier the same day.

Addex Full Year 2009 Financial Results Conference Call:
Date: 23 February 2009
Time: 16:00 CET/15:00 GMT/10:00 EST
Dial-in numbers:

+41 91 610 56 00 (Europe)
+44 207 107 0611 (UK)
+1 866 291 4166 (USA)

Webcast   &   slides   (replay   and  transcript)  will  be  made  available  at
www.addexpharma.com <http://www.addexpharma.com/>.

Addex    Pharmaceuticals   (www.addexpharma.com   <http://www.addexpharma.com/>)
utilizes  its unique proprietary  platform technologies to  discover and develop
allosteric  modulators for human  health. Allosteric modulators  are a different
kind of orally available small molecule therapeutic agent, which we believe will
offer  a  competitive  advantage  over  classical  drugs.  With  15 programs  in
development,   the  Addex  pipeline  demonstrates  the  productivity  and  broad
potential  of our unparalleled platform technologies. The most advanced product,
ADX48621,  an mGluR5 negative allosteric modulator  (NAM), has completed Phase I
testing  and  is  scheduled  to  start  Phase II testing for Parkinson's disease
levodopa associated dyskinesia (PD-LID) later in 2010.
Our  products  and  technology  already  have  proven  their  value  through our
relationships  with four  of the  top 10 pharmaceutical  companies in the world.
Specifically,  under  an  agreement  withOrtho-McNeil-Janssen  Inc., a Johnson &
Johnson  company, ADX71149,  an mGluR2  positive allosteric  modulator (PAM), is
undergoing  Phase  I  clinical  testing  and  has  potential  for  treatment  of
schizophrenia and anxiety. Under two separate agreements with Merck & Co., Inc.,
we  are  developing  PAMs  of  mGluR4  and  mGluR5 as drugs to treat Parkinson's
disease  and  schizophrenia,  respectively.  In  addition, SR-One, the corporate
venture  arm  of  GlaxoSmithKline,  and  Roche  Venture  Fund  have  made equity
investments in Addex.

Chris Maggos
Investor Relations & Communications
Addex Pharmaceuticals
+41 22 884 15 11
chris.maggos@addexpharma.com 

Disclaimer:  The foregoing release contains  forward-looking statements that can
be  identified by terminology such  as "not approvable", "continue", "believes",
"believe",  "will", "remained open  to exploring", "would",  "could", or similar
expressions,   or   by   express   or   implied   discussions   regarding  Addex
Pharmaceuticals  Ltd, its  business, the  potential approval  of its products by
regulatory  authorities,  or  regarding  potential  future  revenues  from  such
products.  Such forward-looking  statements reflect  the current  views of Addex
Pharmaceuticals  Ltd  regarding  future  events,  and  involve known and unknown
risks,  uncertainties  and  other  factors  that  may  cause actual results with
allosteric  modulators of mGluR4, mGluR2, mGluR5 or other therapeutic targets to
be  materially different  from any  future results,  performance or achievements
expressed  or  implied  by  such  statements.  There  can  be  no guarantee that
allosteric  modulators of mGluR4, mGluR2 or mGluR5  will be approved for sale in
any  market  or  by  any  regulatory  authority.  Nor can there be any guarantee
that allosteric  modulators  of  mGluR4,  mGluR2,  mGluR5  or  other therapeutic
targets will achieve any particular levels of revenue (if any) in the future. In
particular,   management's  expectations  regarding   allosteric  modulators  of
mGluR4,  mGluR2, mGluR5 or other therapeutic targets could be affected by, among
other  things, unexpected actions by our partners, unexpected regulatory actions
or delays or government regulation generally; unexpected clinical trial results,
including  unexpected new  clinical data  and unexpected  additional analysis of
existing clinical data; competition in general; government, industry and general
public  pricing pressures; the company's ability to obtain or maintain patent or
other  proprietary intellectual property protection. Should one or more of these
risks  or  uncertainties  materialize,  or  should  underlying assumptions prove
incorrect,  actual results may vary materially from those anticipated, believed,
estimated  or expected.  Addex Pharmaceuticals  is providing  the information in
this  press release  as of  this date  and does  not undertake any obligation to
update  any  forward-looking  statements  contained  in  this press release as a
result of new information, future events or otherwise.


[HUG#1384989]



 --- Ende der Mitteilung  --- 

Addex Pharmaceuticals
12, chemin des Aulx Plan-les-Ouates; Geneva Schweiz

ISIN: CH0029850754;